Patents by Inventor Sébastien Francois Emmanuel Lemaire

Sébastien Francois Emmanuel Lemaire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10544135
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: January 28, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ioannis Nicolaos Houpis, Sebastien Francois Emmanuel Lemaire
  • Publication number: 20190194177
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: April 12, 2012
    Publication date: June 27, 2019
    Applicant: JANSSEN PHARAMCEUTICA NV
    Inventors: Ioannis Nicolaos Houpis, Sebastien Francois Emmanuel Lemaire
  • Publication number: 20180093943
    Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. those in the scheme below: which intermediates and processes are useful in the preparation of the macrocyclic HVC inhibitor Simeprevir.
    Type: Application
    Filed: March 25, 2016
    Publication date: April 5, 2018
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Dominique Paul Michel Depré, Dominic John Ormerod, Andras Horvath, Thomas Shaw Moody, Maude Brossat, Olivier Riant, Nicolas Vriamont, Sébastien Francois Emmanuel Lemaire, Sébastien Nicolas J. Hermant
  • Patent number: 9174971
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 3, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Vittorio Farina, Sebastien François Emmanuel Lemaire, Ioannis N. Houpis
  • Patent number: 8153829
    Abstract: Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol and especially its enantiomer (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-ol, as well as certain novel intermediates for use in such methods are disclosed.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: April 10, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Sébastien François Emmanuel Lemaire, Andras Horvath, Wim Albert Alex Aelterman, Thomas Joachim Landewald Rammeloo
  • Publication number: 20110087017
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: October 14, 2010
    Publication date: April 14, 2011
    Inventors: Vittorio FARINA, Sebastien François Emmanuel Lemaire, Ioannis N. Houpis
  • Publication number: 20100094028
    Abstract: Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol and especially its enantiomer (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-ol, as well as certain novel intermediates for use in such methods.
    Type: Application
    Filed: November 9, 2007
    Publication date: April 15, 2010
    Applicant: TIBOTEC PHARMACEUTICALS LTD
    Inventors: Sébastien François Emmanuel Lemaire, Andras Horvath, Wim Albert Alex Aelterman, Thomas Joachim Landewald Rammeloo